Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions] I would now like to turn the conference over to ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio CareDx, Inc. (Nasdaq: CDNA) — The ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

A total of 641 eligible cases were enrolled from June 2022 to October 2023 from seven hospitals in China. The sensitivity rates for all syndromes ranged from 70.37% to 92.00%, with the highest rate ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the ...

Vektor Medical, a medical technology company transforming cardiac arrhythmia care, announced key milestones achieved in 2025, a year defined by progress, innovation, and growth. Vektor’s flagship ...

Abstract: Objective: Neonatal late-onset sepsis (LOS) is a life-threatening condition in preterm infants in neonatal intensive care units (NICUs), with early detection being crucial for improving ...

NEW YORK – Personalized cancer firm Artera this week presented four studies on its multimodal artificial intelligence (MMAI) digital pathology-based risk stratification platform at the annual ...

For any document version listed below, click on its file name to view it. The current [ ] version of the document is downloaded by default when the document is referenced elsewhere on the site.

Copyright: © 2025 The Author(s). Published by Elsevier Ltd.